Press Releases May 1, 2026 09:00 AM

Diginex confirms $10.56 Share Consideration Price in $1.5B Acquisition

Diginex clarifies share price adjustment following 8-for-1 stock consolidation in $1.5 billion acquisition deal

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
DGNX

Diginex Limited confirms the adjusted share consideration price of $10.56 per share post an 8-for-1 stock consolidation for its previously announced acquisition of Resulticks Global Companies in an all-share transaction valued at $1.5 billion. The transaction terms remain unchanged in aggregate value but the share price and number of shares issued have been adjusted to reflect the recent reverse stock split.

Diginex confirms $10.56 Share Consideration Price in $1.5B Acquisition
DGNX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Diginex is acquiring Resulticks Global Companies in an all-share deal valued at $1.5 billion.
  • An 8-for-1 stock consolidation was executed, adjusting the share consideration price from $1.32 pre-consolidation to $10.56 post-consolidation.
  • Transaction remains subject to closing conditions with no change in total economic value.
  • Sectors impacted include financial technology, RegTech, sustainability reporting, blockchain technology, and AI-driven data analytics.

LONDON, May 01, 2026 (GLOBE NEWSWIRE) -- Diginex Limited (NASDAQ: DGNX) ("Diginex" or the "Company"), a leading provider of Sustainability RegTech solutions, is issuing this clarification in response to questions from market participants regarding the per-share consideration for its previously announced potential acquisition of Resulticks Global Companies Pte Limited ("Resulticks").

As disclosed in the Company's press release dated April 16, 2026 and the related Form 6-K furnished to the U.S. Securities and Exchange Commission, Diginex agreed to acquire Resulticks in an all-share transaction valued at US$1.5 billion, with consideration payable in Diginex ordinary shares at a reference price of US$1.32 per share. That reference price was struck on a pre-consolidation basis, ahead of the 8-for-1 share consolidation that became effective at 9:30 A.M. EDT on April 28, 2026.

To avoid any ambiguity:

  • The aggregate transaction value remains US$1.5 billion, payable entirely in Diginex ordinary shares. The total economic value of the consideration is unchanged, but as is standard practice, the Share Purchase Agreement contains adjustment mechanisms in the event of corporate actions before closing, such as a reverse share split.
  • The pre-consolidation reference price of US$1.32 per share, is therefore adjusted to US$10.56 per share (US$1.32 * 8) on a post-consolidation basis i.e. present-day basis, versus close price on April 30th, 2026 of US$1.82.
  • The pre-consolidation consideration share issuance of 1,133,333,333, is therefore adjusted to 141,666,667 shares on a post-consolidation basis (1,133,333,333 / 8).

References to the US$1.32 figure should therefore not be interpreted as a post-consolidation price, in present day terms the consideration shares are paid at US$10.56. The transaction remains subject to closing conditions.

About Diginex

Diginex Limited (Nasdaq: DGNX; ISIN KYG286871044), headquartered in London, is a sustainable RegTech business that empowers businesses and governments to streamline ESG, climate, and supply chain data collection and reporting. The Company utilizes blockchain, AI, machine learning and data analysis technology to lead change and increase transparency in corporate regulatory reporting and sustainable finance. For more information, please visit https://www.diginex.com/.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may", "will", "expect", "anticipate", "aim", "estimate", "intend", "plan", "believe", "potential", "continue", "is/are likely to" or other similar expressions. Actual results may differ materially. The Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Relations Contacts

Diginex 
Investor Relations 
Email: ir@diginex.com

IR Contact - Europe 
Anna Höffken 
Phone: +49.40.609186.0 
Email: diginex@kirchhoff.de

IR Contact - US 
Jackson Lin 
Lambert by LLYC 
Phone: +1 (646) 717-4593 
Email: jian.lin@llyc.global


Risks

  • Transaction is subject to customary closing conditions which may delay or prevent completion, impacting market confidence.
  • Forward-looking statements indicate potential risks and uncertainties regarding Diginex's future financial condition and results.
  • Market reaction could be muted due to perceived complexities or uncertainties around the share consolidation and transaction timing.

More from Press Releases

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control Jun 14, 2026 Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026